GENE ONLINE|News &
Opinion
Blog

2022-01-18| Technology

New Non-Invasive Test Offers Better Solution for Endometriosis

by GeneOnline
Share To

Endometriosis is a common gynecologic problem, which affects 6-15% of reproductive-age women. There are 176 million women suffering from this disease worldwide at an annual cost of nearly $110 billion dollars. It often presents with painful menstruation, pelvic pain, and infertility, leading to deterioration in the quality of life and high psychological morbidity. Sadly, the average diagnosis delay is 10 years since the occurrence of the first symptom. Despite the high healthcare burden, endometriosis is often diagnosed late – up to an average of 10 years from the onset of the first symptoms.

The reason why there is a long diagnosis delay can be categorized into patient and physician levels. It is hard to differentiate secondary dysmenorrhea (menstrual cramping or pain) from primary forms, and women often conceal the severity of pain to avoid being stigmatized as being unable to bear it. 

Another clinical challenge is the lack of good non-invasive methods for diagnosing the disease. Most women with endometriosis have normal transvaginal ultrasonography (TVUS) results because it is hard to detect small lesions of Stage I endometriosis, the most common stage. Some physicians use serum CA-125 measurement as a biomarker for detecting endometriosis. However, however, CA-125 is limited for endometriosis according to the American College of Obstetricians and Gynecologists. Laparoscopic surgery is the gold standard diagnosis method, but patients need psychological preparation before the surgery and there is a risk of complications. “Therefore, non-invasive and high accuracy screening methods are highly in demand,” said Kevin Kuo, Chief Executive of Gene Health. And that is the reason why Dr. Vivian Yang, Taipei Medical University, has devoted herself to finding a potential biomarker since 2002.

 

Dr. Vivian Yang
Dr. Vivian Yang, Taipei Medical University

 

Dr. Yang’s efforts resulted in the discovery of an isoform of α-1 antitrypsin (isoAAT) in serum, which can be a biomarker for endometriosis. α -1 antitrypsin is a serine protease inhibitor-related to TNF-α signaling.  Rises in isoAAT levels have been observed not just in patients with severe endometriosis, but also in mild and moderate cases, indicating that it may be a good candidate for early detection. Dr. Yang’s lab has also detected decreases in isoAAT levels after GnRH treatment. 

 

 

Many clinical validations have been done in the past few years, a double-blind clinical research shows that a test for isoAAT has a sensitivity of 92% and a specificity of 91%. It is a better blood test compared to CA-125 with a sensitivity of 35%, specificity of 83%, and it is not affected by menstruation. It is an enormous improvement in endometriosis non-invasive screening.

 

From Lab Project to Commercialized Product

 

Kevin Kuo, director of Gene Health, a Taiwanese genetic test company focusing on prenatal tests learned about Dr. Yang’s research at a national conference in Taiwan for the biotechnology and medicine industry in 2017. Seeing this as a great opportunity in clinical application, the two decided to develop a commercial endometriosis blood test, with Kuo contributing his experience in commercialization. Their project began in 2018. 

 

Kevin Kuo
Kevin Kuo, Director of Gene Health

 

To turn the research into a functioning product, Kuo assembled a product development team with Sophia Liu, a specialist in Gene Health, as the main organizer of the project. The project quickly breezed through product validation, drafting of guidelines for delivery, and training programs. Under close collaboration with clinicians, the team managed to conclude project commercialization and introduce the product into the market within half a year. 

 

The endometriosis blood test provided by Gene Health stood out from thousands of exhibition booths at the BIO Asia Conference. It is now a laboratory-developed test (LDT) in Taiwan, used by physicians as a reference for the subsequent treatment of women with menstrual pain and infertility. 

 

Sophia Liu
Sophia Liu, Specialist in Gene Health

 

With the help of the test, service providers can now detect stage I and stage II endometriosis, a feat that was nearly impossible when using TVUS and CA-125. Early diagnosis and treatment can largely decrease the recurrence rate after treatment, and prevent infertility outcomes due to severe endometriosis. For women already suffering from infertility due to endometriosis, medical treatment before ART can improve the pregnancy rate up to two-fold.

 

 

 

By using the endometriosis blood test, clinicians can make an earlier and more informed decision when prescribing medicines, and alleviate the patients’ medical burden by saving time, money and reducing the risk of complications. Dr. Yang and Kuo hope that with the endometriosis blood test, women will no longer have to suffer the monthly pain or infertility brought about by the disease. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Mithra Submits Marketing Approval Application in Japan to Combat Dysmenorrhea
2023-10-26
R&D
Could Bacteria Be Causing Endometriosis?
2023-06-27
GeneOnline’s Weekly News Highlights: June 19-23
2023-06-26
LATEST
Six Game-Changing Cancer Treatments Built for Unstoppable Growth in 2025 – Part II
2024-12-11
Six Game-Changing Cancer Treatments Built for Unstoppable Growth in 2025 – Part I
2024-12-11
Healthcare Revolution: Leeuwenhoek Joins Hands with Key Companies and Experts at Healthcare+ Expo Taiwan 2024
2024-12-11
2024 Taiwan Healthcare+ Expo: Innovations in Five Key Industries
2024-12-11
Core8 Group and MedArmor to Pioneer Vietnam’s First AI x ESG Hospital
2024-12-10
The Future of Generative AI for New Drug Development and Precision Medicine
2024-12-09
How FIRM is Shaping Regenerative Medicine in Japan
2024-12-09
EVENT
Scroll to Top